本文選題：藥品價(jià)格談判 + 價(jià)格協(xié)議��； 參考：《衛(wèi)生經(jīng)濟(jì)研究》2017年05期

【摘要】：根據(jù)國(guó)際主流分類標(biāo)準(zhǔn),將英國(guó)創(chuàng)新藥品價(jià)格協(xié)議分為療效導(dǎo)向和經(jīng)濟(jì)導(dǎo)向兩種類型。對(duì)重點(diǎn)協(xié)議進(jìn)行個(gè)案研究的基礎(chǔ)上進(jìn)行綜合分析,研究各協(xié)議的設(shè)計(jì)因素與實(shí)施機(jī)制,進(jìn)一步探求英國(guó)創(chuàng)新藥品價(jià)格談判協(xié)議在具體實(shí)踐中的制度效益與制度效率,為我國(guó)藥品價(jià)格談判的設(shè)計(jì)提供借鑒。
[Abstract]:According to the international mainstream classification standard, the UK innovative drug price agreement is divided into two types: curative effect-oriented and economic-oriented. On the basis of case study of key agreements, this paper makes a comprehensive analysis, studies the design factors and implementation mechanism of each agreement, and further explores the institutional benefits and efficiency of the innovative drug price negotiation agreement in the UK in practice. It provides reference for the design of drug price negotiation in China.
【作者單位】： 中國(guó)藥科大學(xué)國(guó)際醫(yī)藥商學(xué)院;
【分類號(hào)】：R95
，

本文編號(hào)：2076585